A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways

Tumour Biol. 2016 Nov;37(11):14863-14872. doi: 10.1007/s13277-016-5376-4. Epub 2016 Sep 19.

Abstract

Recent studies have shown that the aqueous, ethanolic extracts and a monomer compound of Paris polyphylla exhibit anticancer activity toward several types of cancer cell lines, but the anticancer activity of (3β,17α,25R)-spirost-5-ene-3,17-diol 3-O-α-L-rhamnopyranosyl-(1 → 2)-β-D-glucopyranoside, a monomer isolated from P. polyphylla (PP), named PP-22, has not been reported previously. In this study, we investigated the effect of PP-22 on human tongue squamous cell carcinoma SCC-15 cells in vitro. MTT assays showed that PP-22 inhibited the growth of SCC-15 cells and had no obvious inhibitory effects on human liver L02 cells. Flow cytometry assays showed that the percentages of apoptotic cells were increased. In addition, cleaved caspase-8, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) could be detected by Western blotting. Flow cytometry also showed that PP-22 triggered S and G2/M phases arrest in SCC-15 cells, and on the other hand, the expression of cyclin A, cyclin E2, cyclin B1, phospho-cell division cycle2 (p-cdc2)(Tyr15), p-Wee1, Myt1, and p53 was upregulated. Moreover, p-p38 levels increased, p-extracellular signal-regulated kinase (ERK) levels decreased, and cdc25B expression was inhibited. Furthermore, the p38/mitogen-activated protein kinase (MAPK) inhibitor SB203580 reversed the increase of the expression level of p38, p-cdc2 (Tyr15), cleaved caspase 3, cleaved PARP, p-p53, and p53 and reversed the decrease in cdc25B expression. In conclusion, these results demonstrated that PP-22 activated p38, inhibited cdc25B, increased p-cdc2 (Tyr15), and triggered S and G2/M phase arrest, as well as activated p53 through the p38-p53 pathway, inhibited the MAPK/ERK pathway, activated the caspase 8/caspase 3 pathway, and triggered the extrinsic apoptotic pathway in SCC-15 cells.

Keywords: Apoptosis; Cell cycle arrest; Rhizoma paridis; SCC-15 cells; p38.

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology
  • Apoptosis / drug effects
  • CDC2 Protein Kinase
  • Carcinoma, Squamous Cell / drug therapy
  • Caspase 3 / metabolism*
  • Caspase 8 / metabolism*
  • Cell Cycle Proteins
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cyclin A1 / biosynthesis
  • Cyclin B1 / biosynthesis
  • Cyclin-Dependent Kinases / metabolism*
  • Cyclins / biosynthesis
  • DNA-Binding Proteins / biosynthesis
  • G2 Phase Cell Cycle Checkpoints / drug effects*
  • Humans
  • Imidazoles / pharmacology
  • Melanthiaceae / metabolism
  • Nuclear Proteins
  • Plant Extracts / pharmacology
  • Poly(ADP-ribose) Polymerases / metabolism
  • Protein-Tyrosine Kinases
  • Pyridines / pharmacology
  • S Phase Cell Cycle Checkpoints / drug effects*
  • Saponins / pharmacology*
  • Tongue Neoplasms / drug therapy
  • Transcription Factors / biosynthesis
  • Tumor Suppressor Protein p53 / biosynthesis
  • cdc25 Phosphatases / metabolism*
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Antineoplastic Agents, Phytogenic
  • CCNA1 protein, human
  • CCNB1 protein, human
  • CCNE2 protein, human
  • Cell Cycle Proteins
  • Cyclin A1
  • Cyclin B1
  • Cyclins
  • DNA-Binding Proteins
  • Imidazoles
  • MYT1 protein, human
  • Nuclear Proteins
  • Plant Extracts
  • Pyridines
  • Saponins
  • Transcription Factors
  • Tumor Suppressor Protein p53
  • spirost-5-ene-3,17-diol 3-O-rhamnopyranosyl-(1-2)-glucopyranoside
  • Poly(ADP-ribose) Polymerases
  • Protein-Tyrosine Kinases
  • WEE1 protein, human
  • CDC2 Protein Kinase
  • CDK1 protein, human
  • Cyclin-Dependent Kinases
  • p38 Mitogen-Activated Protein Kinases
  • CDC25A protein, human
  • CDC25B protein, human
  • cdc25 Phosphatases
  • Caspase 3
  • Caspase 8
  • SB 203580